Subgroup Optimal Decisions in Cost–Effectiveness Analysis

  • E. MorenoEmail author
  • F. J. Vázquez–Polo
  • M. A. Negrín
  • M. Martel–Escobar
Conference paper
Part of the Advances in Intelligent Systems and Computing book series (AISC, volume 805)


In cost–effectiveness analysis (CEA) of medical treatments the optimal treatment is chosen using an statistical model of the cost and effectiveness of the treatments, and data from patients under the treatments. Sometimes these data also include values of certain deterministic covariates of the patients which usually have valuable clinical information that would be incorporated into the statistical treatment selection procedure. This paper discusses the usual statistical models to undertake this task, and the main statistical problems it involves.

The consequence is that the optimal treatments are now given for patient subgroups instead of for the patient population, where the subgroup are defined by those patients that share some covariate values, for instance age, gender, etc. Some of the covariates are non necessarily influential, as typically occurs in regression analysis, and an statistical variable selection procedure is called for. A Bayesian variable selection procedure is presented, and optimal treatments for subgroups defined by the selected covariates are then found.


Cost–effectiveness Bayesian variable selection Optimal treatments 



Research partially supported by Grants ECO2017–85577–P (MINECO, Spain) and CEICANARIAS2017–025 (Canary Islands).


  1. 1.
    Sculpher, M., Gafni, A.: Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ. 10(4), 317–324 (2001)CrossRefGoogle Scholar
  2. 2.
    Willke, R., Glick, H.A., Polsky, D., Schulman, K.: Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. 7, 481–493 (1998)CrossRefGoogle Scholar
  3. 3.
    Willan, A.R., Kowgier, M.E.: Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate. Health Econ. 17(7), 777–791 (2008)CrossRefGoogle Scholar
  4. 4.
    Moreno, E., Girón, F.J., Vázquez-Polo, F.J., Negrín, M.A.: Optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis. Eur. J. Oper. Res. 218(2), 512–522 (2012)MathSciNetCrossRefGoogle Scholar
  5. 5.
    Moreno, E., Girón, F.J., Martínez, M.L., Vázquez-Polo, F.J., Negrín, M.A.: Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition. Eur. J. Oper. Res. 226(1), 173–182 (2013)MathSciNetCrossRefGoogle Scholar
  6. 6.
    Moreno, E., Girón, J., Casella, G.: Posterior model consistency in variable selection as the model dimension grows. Stat. Sci. 30(2), 228–241 (2015)MathSciNetCrossRefGoogle Scholar
  7. 7.
    Moreno, E., Vázquez-Polo, F.J., Negrín, M.A.: Cost-Effectiveness Analysis of Medical Treatments: A Statistical Decision Theory Approach. Chapman & Hall/CRC Biostatistics Series, Boca Raton (2018, in press)Google Scholar
  8. 8.
    León-Novelo, L., Moreno, E., Casella, G.: Objective Bayes model selection in probit models. Stat. Med. 31(4), 353–365 (2012)MathSciNetCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • E. Moreno
    • 1
  • F. J. Vázquez–Polo
    • 2
  • M. A. Negrín
    • 2
  • M. Martel–Escobar
    • 2
  1. 1.Departamento de Estadístca e I.O.Universidad de GranadaGranadaSpain
  2. 2.Dpto. de Métodos CuantitativosUniversidad de Las Palmas de G.C.Las PalmasSpain

Personalised recommendations